



14 March 2019

Proteome Sciences plc
(“Proteome Sciences” or the “Company”)

Notice of Results

The Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2019, at the time of announcing the 2018 full year results which are scheduled for release on 2 April 2019.

Annual General Meeting

The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 30 April 2019. Formal notice of such will be posted to shareholders with the annual report in April.

For further information please contact:

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.